Browsing Tag

#AT-H201

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

Eli Pacheco Apr 21, 2022 0

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20,…

Health

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to…

Eli Pacheco Jan 27, 2022 0

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of…

Health

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Eli Pacheco Jan 19, 2022 0

SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of…

Health

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

Eli Pacheco Sep 30, 2021 0

SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in…